Severe drug-induced skin reactions;Schwere arzneimittelinduzierte Hautreaktionen

Allergologie

Volumn 24, Issue 9, 2001, Pages 419-432

  Mockenhaupt, M ^a   Norgauer, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Erythema exsudativum multiforme majus (EEMM); Stevens Johnson syndrome (SJS); Toxic epidermal necrolysis (TEN)

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; COTRIMOXAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PIROXICAM;

CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DRUG ERUPTION; GERMANY; HISTOPATHOLOGY; HUMAN; PATHOGENESIS; PREVALENCE; REVIEW; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 0034804967     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes
2. Are intravenous immunoglobulins the treatment of Stevens-Johnson syndrome or toxic epidermal necrolysis?
3. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis
4. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme
5. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: A population-based study with particular reference to reactions caused by drugs among outpatients
6. Drug rashes. What are the targets of cell-mediated cytotoxicity?
7. Cutaneous T-cell recruitment in toxic epidermal necrolysis: Further evidence of CD8+ lymphocyte involvement
8. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis
9. Staphylococcal scalded skin syndrome: Clinical features, pathogenesis, and recent microbiological and biochemical developments
10. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis - Preliminary results of a case-control study
11. Autoantibodies to desmoplakin I and II in patients with erythema multiforme
12. Toxic epidermal necrolysis associated with mycoplasma pneumoniae infection
13. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death?
14. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome)
15. Cell death by apoptosis and epidermal biology
16. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids
17. Erythema exsudativum multiforme
18. Efficacy of cyclophosphamide in toxic epidermal necrolysis
19. Plasmapheresis in severe drug-induced toxic epidermal necrolysis
20. Cutaneous reactions to drugs. With special reference to severe bullous mucocutaneous eruptions and sulphonamides. A clinical study
21. An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods
22. Toxic epidermal necrolysis: An eruption resembling scalding of the skin
23. Requiem for toxic epidermal necrolysis
24. The staphylococcal scalded skin syndrome: Development of an experimental model
25. Antirheumatic medication and the risk for severe cutaneous adverse reactions (SCAR)
26. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with antiepileptic therapy
27. Stevens-johnson-syndrom und toxisch epidermale nekrolyse bei AIDS-patienten: Inzidenz und medikamentenanamnese
28. Populationsbezogene erfassung von schweren hautreaktionen in deutschland
29. Clinical reevaluation of erythema exsudativum multiforme majus and Stevens-Johnson syndrome resulting in a different etiology
30. Stellungnahme zum bericht "erfolgreiche therapie des lyell-syndroms mit intravenösen immunglobulinen"
31. Incidence of toxic epidermal necrolysis in Italy
32. Drug-specific cytotoxic T lymphocytes in the skin lesions of a patient with toxic epidermal necrolysis (TEN)
33. Macrophages and tumor necrosis factor-α in toxic epidermal necrolysis
34. Apoptosis as a mechanism of keratinocyte death in toxic epdermal necrolysis
35. Drug-induced toxic epidermal necrolysis treated with cyclosporin
36. Toxic epidermal necrolysis (Lyell's syndrome): Incidence and drug etiology in France, 1981-1985
37. Genetic susceptibility to toxic epidermal necrolysis
38. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
39. Severe adverse cutaneous reactions to drugs
40. Hyperbaric oxygen treatment of toxic epidermal necrolysis
41. Incidence and demography of staphylococcal scalded skin syndrome (SSSS) in Germany
42. Histopathological and epidemiological characteristics of patients with erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
43. Epidemiology of erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990-1992). Structure and results of a population-based registry
44. Schwere arzneimittelinduzierte hautreaktionen: Pemphigus vulgaris, bullöses pemphigoid, generalized bullous fixed drug eruption, erythema exsudativum multiforme majus, Stevens-Johnson-syndrom und toxisch epidermale nekrolyse
45. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West-Germany
46. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity
47. Improving the outcome of patients with toxic epidermal necrolysis and Stevens-Johnson syndrome
48. Epidemiology of adverse cutaneous reactions to drugs
49. A new eruptive fever associated with stomatitis and ophthalmia: Report of two cases in children
50. A population-based study of Stevens-Johnson syndrome: Incidence and antecedent drug exposures
51. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
52. Immunopathology of toxic epidermal necrolysis: Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: An immunopathologic study of five cases
53. Toxic epidermal necrolysis following bone marrow transplantation, study of nine cases
54. Oculocutaneous manifestations of the erythema multiforme/Stevens-Johnson/toxic epidermal necrolysis spectrum
55. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome
56. Metabolic predisposition to cutaneous adverse drug reactions: Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants
57. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis